Epithelial-Mesenchymal Transition: A Potential Therapeutic Goal for Prevention of Wound Fibrosis? by Farahani, Ramin Mostofi Zadeh
LETTERS TO THE EDITOR
Epithelial-Mesenchymal Transition: A
Potential Therapeutic Goal for Prevention
of Wound Fibrosis?
Published 30 November 2006
The skin is a composite structure composed of a superficial epidermis and an underlying
dermis. Wounding of this structure with resultant functional and anatomical disintegra-
tion leads to a cascade of events directed at the restoration of these features. However,
maintenance of anatomical integrity has a higher priority from the standpoint of preserva-
tion of homeostatic equilibrium. The uncoupling of anatomical and functional renovation
due to accelerated wound closure without proper regeneration and spatial organization of
the underlying cellular/extracellular assembly leads to scarring and loss of function. Ep-
ithelialization and contraction are the major mechanisms acting to minimize the exposed
woundsurface.1 Disconnectionofthesetwoprocedures,especiallyforextensivesuperficial
wounds,forexampleburns,mayproveuseful;thepotentialdelaybetweentheseprocedures,
while keeping the epithelialization at an optimum level, provides sufficient time for spatial
organization of the underlying matrix and thereby prevents loss of function.
Fibroblasts and epithelial cells are major regulatory elements of wound contraction
and epithelialization, respectively. Fibroblasts contribute to contraction directly by produc-
ing contractile forces2 and indirectly via differentiating into myofibroblasts.3 The epithe-
lium, once considered to be terminally differentiated, has the ability to differentiate into
fibroblasts.4,5 The occurrence of epithelial-mesenchymal transition (EMT) following ep-
ithelial stress such as inflammation or wound has been documented.4–7 Local expression of
TGF-β, EGF,IGF-II, or FGF-2 facilitates EMT by binding epithelial receptors with ligand-
inducible intrinsic kinase activity.8–11 While during somitogenesis, mesenchymal-epithelial
transition happens,12 this transformation has not been investigated in the wound milieu.
Iwano et al5 suggest that the majority of local fibroblasts develop following EMT from
epithelium. Manipulation of cell fate pathways of the epithelium toward reepithelializa-
tion while diminishing EMT may serve to prevent the aforementioned excessive fibrosis
and the resultant anatomical-functional uncoupling. TGF-β exerts an inhibitory effect on
the proliferating epithelium13 and the EGF/IGF assembly synergistically enhances it.14 It
has been shown that TGF-β exerts an inhibitory effect on EGF.15,16 Therefore, although
speculative, it seems that altering the ratio of TGF-β/EGF in favor of EGF may help re-
duce EMT and consequent fibrosis and scarring. This hypothesis is further supported by
the finding that TGF-β1–null mice show enhanced wound healing, with narrower, sca-
bless wounds. The rate of reepithelialization in the knock-out mice increased such that,
3d ays postwounding, wounds were 90% covered with the neoepidermis compared with
only 22% of the wound surface in controls.17 Furthermore, while neutralizing antibodies
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to TGF-β1 reduced scarring,18 treatment of fetal wounds with different concentrations of
TGF-β1 caused marked scarring of these wounds,19 suggesting a pivotal role for TGF-β
in the scarring. The enhanced epithelialization and diminished scarring—that is, discon-
nection of these two procedures—and the resultant anatomical-functional uncoupling are
in agreement with the proposed hypothesis.
This prospective modality may be useful for wounds where excessive contraction and
fibrosis is probable, for example, extensive burns. Future research may be directed toward
testing the hypothesis via EMT markers and also developing therapeutic strategies for
regulation of the TGF/EGF ratio.
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